Moderna, Inc. (MRNA)
What's Happening With Moderna Stock?
Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine developed in collaboration with Merck, which yielded encouraging outcomes in minimizing melanoma recurrence when paired with Keytruda immunotherapy.
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally.
Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
In a blast from the past, COVID-19 vaccine developer Moderna NASDAQ: MRNA just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three years.
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna expects 2025 revenue of $1.9B, above guidance
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. The company also raised its 2025 GAAP operating expense outlook by $200 million to a range of $5 to $5.2 billion and projects a year-end cash balance of approximately $8.1 billion, including a $0.6 billion drawdown from a recently announced $1.5 billion term loan facility.
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below revenue levels achieved during the COVID-19 pandemic.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2.0 billion and outlined its pipeline milestones for 2026-28, with the company continuing to focus on Covid-19 as its near-term revenue driver. In its annual letter, Moderna highlighted that its Covid vaccines remain central to 2026, with the mNEXSPIKE vaccine representing roughly 24% of all US retail Covid vaccinations in 2025 and nearly one-third of vaccinations among adults aged 65 and older.
